[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625320":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":18,"locations":23,"responsibleParty":56,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":18,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":18,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Mailed Medications","There is no comparison arm. This pilot study evaluates the feasibility of mailing medications to patients.",[12],"Other: strategy of mailing buprenorphine",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"strategy of mailing buprenorphine","This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Allison Smith, MD","PRINCIPAL_INVESTIGATOR",[24,43],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"NOT_YET_RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-79.93275,32.77632,{"lat":35,"lon":34},[38,42],{"name":21,"role":39,"phone":40,"phoneExt":18,"email":41},"CONTACT","843-792-2100","smithall@musc.edu",{"name":21,"role":22,"phone":18,"phoneExt":18,"email":18},{"facility":5,"status":44,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":45,"geoPoint":47,"contacts":48},"RECRUITING",{"type":32,"coordinates":46},[34,35],{"lat":35,"lon":34},[49,52,55],{"name":50,"role":39,"phone":51,"phoneExt":18,"email":41},"Primary Investigator, MD","843-792-0686",{"name":53,"role":39,"phone":18,"phoneExt":18,"email":54},"Research Coordinator, BS","schneidh@musc.edu",{"name":21,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":22,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Allison Smith","Associate Professor-Faculty",[60],{"name":61,"class":62},"National Institute on Drug Abuse (NIDA)","NIH","100625320","early-phase-1-pilot-of-mailing-buprenorphine-100625320",false,"NCT07421102","Pilot of Mailing Buprenorphine","A Pragmatic Remote Approach to Improve Transitions of Care and Retention in Opioid Use Disorder Treatment","Inclusion Criteria:\n\n* Age ≥ 18\n* English-speaking\n* Diagnosed with OUD and initiated on buprenorphine during hospitalization\n* Discharging to a South Carolina address with a stable mailbox\n* Access to phone or computer\n\nExclusion Criteria:\n\n* Active psychosis or suicidal ideation\n* Severe medical or neurocognitive impairment\n* Pending incarceration","ALL","18 Years",{"count":73,"type":74},20,"ESTIMATED","INTERVENTIONAL",[77],"EARLY_PHASE1","This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access.",[80],"Opioid Use Disorder",[82,83,84,85],"mailing buprenorphine","transitions of care","opioid use disorder","barriers to buprenorphine","2026-07-29",{"date":88,"type":89},"2026-07-30","ACTUAL",{"date":91,"type":89},"2026-04-08",{"date":93,"type":74},"2027-03",{"name":5,"class":6},2]